Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment

Intensive Care Medicine

Volumn 35, Issue 2, 2009, Pages 206-214

  Guery, Benoît P ^a   Arendrup, Maiken C ^b   Auzinger, Georg ^c   Azoulay, Élie ^d   Borges Sá, Márcio ^e   Johnson, Elizabeth M ^f   Müller, Eckhard ^g   Putensen, Christian ^h   Rotstein, Coleman ⁱ   Sganga, Gabriele ^j   Venditti, Mario ^k   Zaragoza Crespo, Rafael ^l   Kullberg, Bart Jan ^m  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b STATENS SERUM INSTITUT   (Denmark)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d SAINT LOUIS HOSPITAL   (France)

^e HOSPITAL SON LLÀTZER   (Spain)

^f NHS BLOOD AND TRANSPLANT   (United Kingdom)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h UNIVERSITY OF BONN   (Germany)

ⁱ TORONTO GENERAL HOSPITAL   (Canada)

^j CATHOLIC UNIVERSITY   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Antifungal; Azole; Candida; Candidiasis; Echinocandins; Intensive care; Invasive candidiasis; Polyenes

Indexed keywords

ALBUMIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CREATININE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; MICAFUNGIN; POLYENE; VORICONAZOLE;

ALBUMIN BLOOD LEVEL; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; ASPERGILLOSIS; BACTERIAL COLONIZATION; BODY WEIGHT; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CATHETER INFECTION; CATHETER REMOVAL; CHRONOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG PENETRATION; DRUG UTILIZATION; EARLY INTERVENTION; EUROPE; FUNGAL COLONIZATION; FUNGICIDAL ACTIVITY; HEMODYNAMICS; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE; INVASIVE CANDIDIASIS; KIDNEY CLEARANCE; KIDNEY FAILURE; LAPAROTOMY; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORALITY; MORTALITY; MUCOSA INFLAMMATION; NEUTROPENIA; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SURGICAL RISK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY CATHETER;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BACTEREMIA; CANDIDA ALBICANS; CANDIDIASIS; FLUCONAZOLE; HUMANS; INTENSIVE CARE UNITS;

EID: 59849102023     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-008-1339-6     Document Type: Review

References (44)

1. MD Parkins DM Sabuda S Elsayed KB Laupland 2007 Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections J Antimicrob Chemother 60 613 618
2. J Nolla-Salas A Sitges-Serra C Leon-Gil J Martinez-Gonzalez MA Leon-Regidor P Ibanez-Lucia JM Torres-Rodriguez 1997 Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU Intensive Care Med 23 23 30
3. KW Garey M Rege MP Pai DE Mingo KJ Suda RS Turpin DT Bearden 2006 Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study Clin Infect Dis 43 25 31
4. M Morrell VJ Fraser MH Kollef 2005 Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality Antimicrob Agents Chemother 49 3640 3645
5. J Garnacho-Montero JL Garcia-Garmendia A Barrero-Almodovar FJ Jimenez-Jimenez C Perez-Paredes C Ortiz-Leyba 2003 Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis Crit Care Med 31 2742 2751
6. A Kumar D Roberts KE Wood B Light JE Parrillo S Sharma R Suppes D Feinstein S Zanotti L Taiberg D Gurka A Kumar M Cheang 2006 Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med 34 1589 1596
7. WT Hughes D Armstrong GP Bodey EJ Bow AE Brown T Calandra R Feld PA Pizzo KV Rolston JL Shenep LS Young 2002 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis 34 730 751
8. J Garbino DP Lew JA Romand S Hugonnet R Auckenthaler D Pittet 2002 Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination Intensive Care Med 28 1708 1717
9. P Eggimann P Francioli J Bille R Schneider MM Wu G Chapuis R Chiolero A Pannatier J Schilling S Geroulanos MP Glauser T Calandra 1999 Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients Crit Care Med 27 1066 1072
10. RK Pelz PA Lipsett SM Swoboda M Diener-West JM Hammond CW Hendrix 2000 The diagnostic value of fungal surveillance cultures in critically ill patients Surg Infect (Larchmt) 1 273 281
11. P Manzoni I Stolfi L Pugni L Decembrino C Magnani G Vetrano E Tridapalli G Corona C Giovannozzi D Farina R Arisio F Merletti M Maule F Mosca R Pedicino M Stronati M Mostert G Gomirato 2007 A multicenter, randomized trial of prophylactic fluconazole in preterm neonates N Engl J Med 356 2483 2495
12. M Cruciani F de Lalla C Mengoli 2005 Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis Intensive Care Med 31 1479 1487
13. MA Pfaller DJ Diekema 2007 Epidemiology of invasive candidiasis: a persistent public health problem Clin Microbiol Rev 20 133 163
14. JH Rex JD Sobel 2001 Prophylactic antifungal therapy in the intensive care unit Clin Infect Dis 32 1191 1200
15. M Bassetti E Righi A Costa R Fasce MP Molinari R Rosso FB Pallavicini C Viscoli 2006 Epidemiological trends in nosocomial candidemia in intensive care BMC Infect Dis 6 21
16. AC Pasqualotto WL Nedel TS Machado LC Severo 2006 Risk factors and outcome for nosocomial breakthrough candidaemia J Infect 52 216 222
17. M Krogh-Madsen MC Arendrup L Heslet JD Knudsen 2006 Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient Clin Infect Dis 42 938 944
18. TR Rocco SE Reinert HH Simms 2000 Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance Arch Surg 135 160 165
19. KW Garey MM Neuhauser DT Bearden JP Cannon RE Lewis LO Gentry DP Kontoyiannis 2006 Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study Mycoses 49 226 231
20. R Piarroux F Grenouillet P Balvay V Tran G Blasco L Millon A Boillot 2004 Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients Crit Care Med 32 2443 2449
21. AC Reboli C Rotstein PG Pappas SW Chapman DH Kett D Kumar R Betts M Wible BP Goldstein J Schranz DS Krause TJ Walsh 2007 Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2472 2482
22. MM Levy MP Fink JC Marshall E Abraham D Angus D Cook J Cohen SM Opal JL Vincent G Ramsay 2003 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference Crit Care Med 31 1250 1256
23. J Mora-Duarte R Betts C Rotstein AL Colombo L Thompson-Moya J Smietana R Lupinacci C Sable N Kartsonis J Perfect 2002 Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2020 2029
24. MJ DiNubile RJ Lupinacci KM Strohmaier CA Sable NA Kartsonis 2007 Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial J Crit Care 22 237 244
25. PG Pappas CM Rotstein RF Betts M Nucci D Talwar JJ De Waele JA Vazquez BF Dupont DL Horn L Ostrosky-Zeichner AC Reboli B Suh R Digumarti C Wu LL Kovanda LJ Arnold DN Buell 2007 Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 883 893
26. TH Nguyen T Hoppe-Tichy HK Geiss AC Rastall S Swoboda J Schmidt MA Weigand 2007 Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit J Antimicrob Chemother 60 100 106
27. L Ostrosky-Zeichner AM Oude Lashof BJ Kullberg JH Rex 2003 Voriconazole salvage treatment of invasive candidiasis Eur J Clin Microbiol Infect Dis 22 651 655
28. BJ Kullberg JD Sobel M Ruhnke PG Pappas C Viscoli JH Rex JD Cleary E Rubinstein LW Church JM Brown HT Schlamm IT Oborska F Hilton MR Hodges 2005 Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 1435 1442
29. BJ Spellberg SG Filler JE Edwards Jr 2006 Current treatment strategies for disseminated candidiasis Clin Infect Dis 42 244 251
30. ME Bougnoux G Kac P Aegerter C d'Enfert JY Fagon 2008 Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome Intensive Care Med 34 292 299
31. JH Rex PG Pappas AW Karchmer J Sobel JE Edwards S Hadley C Brass JA Vazquez SW Chapman HW Horowitz M Zervos D McKinsey J Lee T Babinchak RW Bradsher JD Cleary DM Cohen L Danziger M Goldman J Goodman E Hilton NE Hyslop DH Kett J Lutz RH Rubin WM Scheld M Schuster B Simmons DK Stein RG Washburn L Mautner TC Chu H Panzer RB Rosenstein J Booth 2003 A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 1221 1228
32. K Darling J Singh D Wilks 2000 Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC) J Infect 40 92 94
33. RA Smego Jr JR Perfect DT Durack 1984 Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis Rev Infect Dis 6 791 801
34. N Singh AP Limaye G Forrest N Safdar P Munoz K Pursell S Houston F Rosso JG Montoya P Patton R Del Busto JM Aguado RA Fisher GB Klintmalm R Miller MM Wagener RE Lewis DP Kontoyiannis S Husain 2006 Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study Transplantation 81 320 326
35. Y Golan MP Wolf SG Pauker JB Wong S Hadley 2005 Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis Ann Intern Med 143 857 869
36. H Chen KJ Suda RS Turpin MP Pai DT Bearden KW Garey 2007 High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis Curr Med Res Opin 23 1057 1065
37. SH Aliyu DA Enoch II Abubakar R Ali AJ Carmichael M Farrington AM Lever 2006 Candidaemia in a large teaching hospital: a clinical audit QJM 99 655 663
38. VJ Fraser M Jones J Dunkel S Storfer G Medoff WC Dunagan 1992 Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality Clin Infect Dis 15 414 421
39. JH Rex JE Bennett AM Sugar PG Pappas J Serody JE Edwards RG Washburn 1995 Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group Clin Infect Dis 21 994 996
40. I Raad H Hanna M Boktour E Girgawy H Danawi M Mardani D Kontoyiannis R Darouiche R Hachem GP Bodey 2004 Management of central venous catheters in patients with cancer and candidemia Clin Infect Dis 38 1119 1127
41. T Gumbo 2007 Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies Curr Opin Infect Dis 20 587 591
42. C Wagner W Graninger E Presterl C Joukhadar 2006 The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications Pharmacology 78 161 177
43. R Bellmann 2007 Clinical pharmacokinetics of systemically administered antimycotics Curr Clin Pharmacol 2 37 58
44. L Ostrosky-Zeichner JH Rex PG Pappas RJ Hamill RA Larsen HW Horowitz WG Powderly N Hyslop CA Kauffman J Cleary JE Mangino J Lee 2003 Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States Antimicrob Agents Chemother 47 3149 3154